On Apr. 1, 2020, Amgen announced it had consummated the purchase from Astellas of 49% of shares of Amgen Astellas BioPharma K.K., a joint venture between Amgen and Astellas established in 2013. AABP, which is now a wholly-owned Amgen affiliate in Japan renamed Amgen K.K., has enabled Amgen to build a strong presence in Japan as it advances treatments for serious illnesses.